RecruitingNCT06733987
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
40 participants
Start Date
Aug 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken: * before starting treatment with pembrolizumab. * undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients of both sexes aged ≥ 18 years at enrollment
- Patients affected by cHL R/R candidate to receive a treatment with Pembrolizumab
- Signature of informed consent
Exclusion Criteria1
- none
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06733987
Related Trials
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT050924511 location
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
NCT056156361 location
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
NCT060593913 locations
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT036815616 locations
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828428 locations